UCLA
UCLA
Los Angeles, California, United States80 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 1 | 2026-10-09 | NCT04929223 | |
| A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | cancer, neoplasm | Active, not recruiting | Phase 3 | 2026-10-08 | NCT03148418 | |
| ID-ENTITY Trial- Evaluating Serial T-ID Monitoring | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, kidney disorder, urinary system disorder | Enrolling by invitation | Not stated | 2026-10-06 | NCT07393594 | |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Adnexal Diseases, Carcinoma, Ovarian Epithelial, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, head and neck squamous cell carcinoma, intestinal disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, rectal disorder, skin squamous cell carcinoma, squamous cell carcinoma, squamous cell lung carcinoma, squamous cell neoplasm | Recruiting | Phase 1 | 2026-10-06 | NCT04429542 | |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | Fibrosis, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiratory Hypersensitivity, hypersensitivity pneumonitis, immune system disorder, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-10-05 | NCT06329401 | |
| Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 3 | 2026-10-05 | NCT05902169 | |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, neoplasm, neuroendocrine neoplasm, paraganglioma, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-10-02 | NCT07282587 | |
| A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT) | Patients With Chemotherapy-Induced Thrombocytopenia | Recruiting | Phase 3 | 2026-10-01 | NCT07286032 | |
| A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 3 | 2026-09-28 | NCT06919965 | |
| A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | Skin and Connective Tissue Diseases, connective tissue disorder, diffuse scleroderma, skin disorder, systemic sclerosis | Recruiting | Phase 2 | 2026-09-28 | NCT06470048 | |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, breast carcinoma in situ, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, neoplasm | Recruiting | Phase 2 | 2026-09-28 | NCT06075953 | |
| A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Active, not recruiting | Phase 2 | 2026-09-28 | NCT05242471 | |
| A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis | Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-28 | NCT04033445 | |
| A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) | Bone Marrow Failure Disorders, Hemic and Lymphatic Diseases, anemia, aplastic anemia, bone marrow disorder, hematologic disorder | Active, not recruiting | Phase 3 | 2026-09-25 | NCT05600426 | |
| A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT05488314 | |
| A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose | Infections, Mononegavirales infectious disease, Paramyxoviridae infectious disease, Pneumovirus Infections, RNA Virus Infections, respiratory syncytial virus infectious disease, viral infectious disease | Recruiting | Phase 3 | 2026-09-24 | NCT06866405 | |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2026-09-23 | NCT05320198 | |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | Phase 3 | 2026-09-17 | NCT07217717 | |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-09-17 | NCT07217704 | |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 1 | 2026-09-16 | NCT07080242 | |
| A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] | Skin and Connective Tissue Diseases, connective tissue disorder, dermatomyositis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, skin disorder | Recruiting | Phase 3 | 2026-09-15 | NCT05895786 | |
| Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | Recruiting | Phase 2 | 2026-09-08 | NCT07286292 | |
| BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis | Deep Vein Thrombosis, Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, thrombotic disease, vascular disorder | Active, not recruiting | Not applicable | 2026-09-08 | NCT05003843 | |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | CD4+/CD56+ hematodermic neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Skin and Connective Tissue Diseases, acute myeloid leukemia, bone marrow disorder, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant histiocytosis, myeloid leukemia, myeloproliferative neoplasm, neoplasm, skin disorder, skin neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-04 | NCT03386513 | |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | Skin and Connective Tissue Diseases, connective tissue disorder, diffuse scleroderma, skin disorder, systemic sclerosis | Active, not recruiting | Phase 2 | 2026-09-02 | NCT06655896 |